<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	>
<channel>
	<title>Comments on: To Boost Growth, Lilly Tries A Shot Of&#8230; Diabetes</title>
	<atom:link href="http://www.pharmalot.com/2008/03/to-boost-growth-lilly-tries-a-shot-of-diabetes/feed" rel="self" type="application/rss+xml" />
	<link>http://www.pharmalot.com/2008/03/to-boost-growth-lilly-tries-a-shot-of-diabetes/</link>
	<description>News, Comment and Conversation</description>
	<pubDate>Mon, 22 Mar 2010 14:31:11 +0000</pubDate>
	<generator>http://wordpress.org/?v=2.6.2</generator>
		<item>
		<title>By: Melody</title>
		<link>http://www.pharmalot.com/2008/03/to-boost-growth-lilly-tries-a-shot-of-diabetes/#comment-213802</link>
		<dc:creator>Melody</dc:creator>
		<pubDate>Mon, 17 Mar 2008 18:23:56 +0000</pubDate>
		<guid isPermaLink="false">http://www.pharmalot.com/2008/03/to-boost-growth-lilly-tries-a-shot-of-diabetes/#comment-213802</guid>
		<description>Lilly's direction and solutions are predictable, and hollow. But, fortunately for them (not their patients), they have a captive market (at least in the Type 1 population), don't they.

Their solutions are akin to soothing a crying infant. A disconnected parent will not ascertain if an infant is hungry, or uncomfortable, or in pain. He/she will merely stuff a binky, a rattle, or a toy in little grasping hands. Fortunately, the child will become verbal in what is considered a short timespan, and soon speak for himself. Type 1 diabetics have had one after another of inferior medications foisted on them; they have been offered one shiny techno-gadget after another to quell their noise. Sadly, morbidy and mortality have not improved to a significant degree; complications continue unabated; and a cure is still 'only five years away.' 

Lilly's plan to return to their core business may please shareholders. Someday, however, the patient-base may, like the infant, find its voice. Then again, maybe not.</description>
		<content:encoded><![CDATA[<p>Lilly&#8217;s direction and solutions are predictable, and hollow. But, fortunately for them (not their patients), they have a captive market (at least in the Type 1 population), don&#8217;t they.</p>
<p>Their solutions are akin to soothing a crying infant. A disconnected parent will not ascertain if an infant is hungry, or uncomfortable, or in pain. He/she will merely stuff a binky, a rattle, or a toy in little grasping hands. Fortunately, the child will become verbal in what is considered a short timespan, and soon speak for himself. Type 1 diabetics have had one after another of inferior medications foisted on them; they have been offered one shiny techno-gadget after another to quell their noise. Sadly, morbidy and mortality have not improved to a significant degree; complications continue unabated; and a cure is still &#8216;only five years away.&#8217; </p>
<p>Lilly&#8217;s plan to return to their core business may please shareholders. Someday, however, the patient-base may, like the infant, find its voice. Then again, maybe not.</p>
]]></content:encoded>
	</item>
</channel>
</rss>
